MOBERG DERMA REPORTS POSITIVE CLINICAL RESULTS FOR EMTRIX

Moberg Derma AB today reports positive results from a clinical trial of Emtrix. The trial included 75 patients with nail fungus (onychomycosis) and the results showed that 92% of the patients improved after 8 weeks of treatment. Already after 2 weeks, 77% of the patients were improved.

The open clinical trial was conducted at two clinical centers in Sweden during the second half of 2010. The purpose was to investigate early treatment effects of Emtrix. The patients were followed-up after 2, 4 and 8 weeks treatment with Emtrix.

“The rapid visible improvement of the nail is increasing patients' motivation to continue treatment until complete cure and the outgrowth of a clear nail. The results from this clinical trial provide additional support for upcoming launches in new markets”, comments Moberg Dermas CEO, Peter Wolpert.

About Emtrix® and nail diseases
Emtrix® is a prescription free, topical nail product and has the potential to become first-line treatment for common nail disorders. Launch of Emtrix® was initiated in the first markets in September 2010. Safety and efficacy has been demonstrated in several clinical studies including more than 500 patients. Emtrix® has a unique and rapid mechanism of action which brings visible improvements after two weeks of treatment.

Nail fungus is the most common nail disease and afflicts approximately 10% of the general population and is more common in the elderly. The estimated global market potential exceeds USD 1 billion. The untapped potential is significant since many patients remain untreated. It is generally recognized that there is a need for new efficacious and safe topical treatments.

For further information, please contact:

Peter Wolpert, President and CEO of Moberg Derma
Telephone: +46 8 522 307 00
Mobile: +46 735 71 35
E-mail: peter.wolpert@mobergderma.se

About Moberg Derma

Moberg Derma AB (publ.), based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company’s products are based on proven compounds, which reduce time to market, development costs and risk. The portfolio covers projects in the preclinical phase to approved and launched products. The company began operations at the Karolinska Institute in Stockholm in 2006. Moberg Derma is owned by institutional and private investors, Board and management. For further information, please visit: www.mobergderma.se

Tags: